GB9423380D0
(en)
*
|
1994-11-19 |
1995-01-11 |
Kodak Ltd |
Chemical supply cartridge
|
IT1285757B1
(it)
*
|
1996-07-15 |
1998-06-18 |
Gipco Srl |
Apparecchiatura perfezionata per lo sviluppo di materiale fotosensibile
|
US6082908A
(en)
*
|
1997-07-14 |
2000-07-04 |
Gipco S.R.L. |
Apparatus for processing a photosensitive medium
|
EP1014182A1
(de)
*
|
1998-12-19 |
2000-06-28 |
Eastman Kodak Company |
Nachfüllmethode
|
GB0130184D0
(en)
*
|
2001-12-18 |
2002-02-06 |
Eastman Kodak Co |
Low volume drum processor
|
SI1983000T1
(sl)
|
2003-11-21 |
2015-12-31 |
Ucb Biopharma Sprl |
Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
EP1740617B1
(de)
|
2004-04-23 |
2013-10-16 |
BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten |
Verfahren zur behandlung von erkrankungen, die mit t-zellen im zusammenhang stehen, durch eliminierung von icos-positiven zellen in vivo
|
DK1960430T3
(da)
|
2005-12-09 |
2015-01-05 |
Ucb Pharma Sa |
Antistofmolekyler der har specificitet for humant il-6
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP2535351A3
(de)
|
2007-09-26 |
2013-04-03 |
UCB Pharma S.A. |
Antikörperfusionen mit Doppelspezifität
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
US8614295B2
(en)
|
2009-02-17 |
2013-12-24 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human OX40
|
GB0903207D0
(en)
|
2009-02-25 |
2009-04-08 |
Ucb Pharma Sa |
Method for expressing multimeric proteins
|
US20110313138A1
(en)
|
2009-02-25 |
2011-12-22 |
Ucb Pharma, S.A. |
Method for Producing Proteins
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
CN102781963B
(zh)
|
2009-10-27 |
2018-02-16 |
Ucb医药有限公司 |
功能修饰性NAv1.7抗体
|
GB201001791D0
(en)
|
2010-02-03 |
2010-03-24 |
Ucb Pharma Sa |
Process for obtaining antibodies
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
EA037071B1
(ru)
|
2011-01-14 |
2021-02-02 |
Юсб Байофарма Срл |
Молекулы антител, которые связываются с il-17a и il-17f
|
EP3617227A3
(de)
|
2011-09-16 |
2020-06-03 |
UCB Biopharma SRL |
Neutralisierende antikörpern gegen das haupt exotoxin tcda von clostridium difficile
|
CA2856216C
(en)
|
2011-11-11 |
2021-01-12 |
Ucb Pharma S.A. |
Albumin binding antibodies and binding fragments thereof
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
WO2014001557A1
(en)
|
2012-06-28 |
2014-01-03 |
Ucb Pharma S.A. |
A method for identifying compounds of therapeutic interest
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
AU2014338864C1
(en)
|
2013-10-25 |
2020-07-16 |
Akamis Bio Limited |
Oncolytic adenoviruses armed with heterologous genes
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
CN113940996A
(zh)
|
2015-05-27 |
2022-01-18 |
Ucb生物制药私人有限公司 |
用于治疗神经系统疾病的方法
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
AU2016347471B2
(en)
|
2015-10-27 |
2023-08-03 |
UCB Biopharma SRL |
Methods of treatment using anti-IL-17A/F antibodies
|
EP3452506A1
(de)
|
2016-05-01 |
2019-03-13 |
UCB Biopharma SPRL |
Affinitätsmanipulierte bindungsdomäne für serumproteinträger
|
JP2020500834A
(ja)
|
2016-08-26 |
2020-01-16 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
マクロファージ刺激タンパク質受容体(又はRON(Recepteur d′Origine Nantais))抗体及びその使用
|
US20190194690A1
(en)
|
2016-08-29 |
2019-06-27 |
Psioxus Therapeutics Limited |
Adenovirus armed with bispecific t cell engager (bite)
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
EP3565840A1
(de)
*
|
2017-01-06 |
2019-11-13 |
Crescendo Biologics Limited |
Einzeldomänenantikörper gegen programmierten zelltod (pd-1)
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
US20200171150A1
(en)
|
2017-05-19 |
2020-06-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies
|
PT3630143T
(pt)
|
2017-06-01 |
2023-08-29 |
Akamis Bio Ltd |
Vírus oncolítico e método
|
US20200407422A1
(en)
|
2017-09-05 |
2020-12-31 |
GLAdiator Biosciences, Inc. |
A method of intracellular delivery
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
SG11202012312UA
(en)
|
2018-06-18 |
2021-01-28 |
UCB Biopharma SRL |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
AR117653A1
(es)
|
2018-10-16 |
2021-08-25 |
UCB Biopharma SRL |
Método para tratamiento de miastenia grave
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
SG11202109545VA
(en)
|
2019-03-26 |
2021-10-28 |
Aslan Pharmaceuticals Pte Ltd |
Treatment employing anti-il-13r antibody or binding fragment thereof
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
US20230374158A1
(en)
|
2020-10-13 |
2023-11-23 |
Almirall, S.A. |
Bispecific molecules and methods of treatment using the same
|
MX2023004436A
(es)
|
2020-10-15 |
2023-05-08 |
UCB Biopharma SRL |
Moleculas de union que multimerizan cd45.
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
WO2023075702A1
(en)
|
2021-10-29 |
2023-05-04 |
Aslan Pharmaceuticals Pte Ltd |
Anti-il-13r antibody formulation
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
WO2023163659A1
(en)
|
2022-02-23 |
2023-08-31 |
Aslan Pharmaceuticals Pte Ltd |
Glycosylated form of anti-il13r antibody
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2024043837A1
(en)
|
2022-08-26 |
2024-02-29 |
Aslan Pharmaceuticals Pte Ltd |
High concentration anti-il13r antibody formulation
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|